APR September/October 2020 - 15
Ajinomoto Bio-Pharma Services
11040 Roselle St.
San Diego, CA 92121
(T): (858)882-0123 (F): (858)882-0133
Email: info@US.AjiBio-Pharma.com
www.facebook.com/AjiBioPharma
www.linkedin.com/company/ajibio-pharma-services/
twitter.com/AjiBioPharma
www.AjiBio-Pharma.com
COMPANY DESCRIPTION
SERVICES & CAPABILITES
Ajinomoto Bio-Pharma Services is a fully integrated contract
Phase-Appropriate Services: Our complete range of process and
development and manufacturing organization, with sites in Belgium,
analytical development capabilities offer the tools to address your
United States, Japan, and India, providing comprehensive process
needs, whether it is producing small quantities for early testing or in
development services, cGMP manufacturing and drug product fill finish
developing robust, reliable and scalable processes that will enable a
services for small and large molecule APIs and intermediates.
strong commercial advantage.
Ajinomoto Bio- Pharma Services offers a broad range of innovative
Broad Range of Capabilities: Over 40 years of CDMO experience
platforms and capabilities for pre-clinical and pilot programs to
providing a range of manufacturing capabilities enables us to deliver
commercial quantities, including Corynex® protein expression
technology, oligonucleotide synthesis, antibody drug conjugations
(ADC), high potency APIs (HPAPI), continuous flow manufacturing and
the flexibility and guidance to meet different drug product needs from
emerging therapeutics to life cycle management.
more. Ajinomoto Bio-Pharma Services is dedicated to providing a high
*
Drug product fill finish
level of quality and service to meet our client's needs.
*
Small molecule manufacturing
Ajinomoto Bio-Pharma Services is your trusted manufacturing partner,
*
Large molecule manufacturing
providing a broad range of capabilities, regulatory excellence, and
*
Oligonucleotide and peptide synthesis
*
ADC development and manufacturing
extensive experience, helping you navigate production challenges,
provide solutions to your development process, and deliver your new
therapies to patients who need it most.
Advanced Technologies: Our services are enhanced by a portfolio of
innovative and advanced technologies that enable robust, scalable,
cost- and time-efficient processes for large and small molecule
manufacturing. We are continuously developing new solutions to
improve manufacturing processes.
Regulatory Support: With and impressive and successful track record,
we are well positioned to advise you on regulatory strategies and
navigate hurdle to achieve your program goals. We provide strong, yet
flexible quality management to ensure continued program success.
MARKETS SERVED
Experience the Power to Make
Our integrated global network for large and small molecule
We have the capacity and know-how to manage projects from preclinical
development and manufacturing has sites in Europe, North America,
stage to commercialization successfully, but what truly differentiates us
and Asia, providing the infrastructure and local support to meet your
is our dedication to quality and our commitment to fostering trusted
drug process development and manufacturing needs.
partnerships. We're looking forward to hearing from you.
www.americanpharmaceuticalreview.com
Ajinomoto_APR2020Profile.indd
APR_SeptOct2020.indd
15
1
|
| 15
10/2/20
9/29/20 11:45
8:13 PM
AM
http://www.facebook.com/AjiBioPharma
http://www.linkedin.com/company/ajibio-pharma-services/
http://www.twitter.com/AjiBioPharma
http://www.AjiBio-Pharma.com
http://www.americanpharmaceuticalreview.com
APR September/October 2020
Table of Contents for the Digital Edition of APR September/October 2020
Table of Contents
APR September/October 2020 - Cover1
APR September/October 2020 - Cover2
APR September/October 2020 - 1
APR September/October 2020 - 2
APR September/October 2020 - Table of Contents
APR September/October 2020 - 4
APR September/October 2020 - 5
APR September/October 2020 - 6
APR September/October 2020 - 7
APR September/October 2020 - 8
APR September/October 2020 - 9
APR September/October 2020 - 10
APR September/October 2020 - 11
APR September/October 2020 - 12
APR September/October 2020 - 13
APR September/October 2020 - 14
APR September/October 2020 - 15
APR September/October 2020 - 16
APR September/October 2020 - 17
APR September/October 2020 - 18
APR September/October 2020 - 19
APR September/October 2020 - 20
APR September/October 2020 - 21
APR September/October 2020 - 22
APR September/October 2020 - 23
APR September/October 2020 - 24
APR September/October 2020 - 25
APR September/October 2020 - 26
APR September/October 2020 - 27
APR September/October 2020 - 28
APR September/October 2020 - 29
APR September/October 2020 - 30
APR September/October 2020 - 31
APR September/October 2020 - 32
APR September/October 2020 - 33
APR September/October 2020 - 34
APR September/October 2020 - 35
APR September/October 2020 - 36
APR September/October 2020 - 37
APR September/October 2020 - 38
APR September/October 2020 - 39
APR September/October 2020 - 40
APR September/October 2020 - 41
APR September/October 2020 - 42
APR September/October 2020 - 43
APR September/October 2020 - 44
APR September/October 2020 - 45
APR September/October 2020 - 46
APR September/October 2020 - 47
APR September/October 2020 - 48
APR September/October 2020 - 49
APR September/October 2020 - 50
APR September/October 2020 - 51
APR September/October 2020 - 52
APR September/October 2020 - 53
APR September/October 2020 - 54
APR September/October 2020 - 55
APR September/October 2020 - 56
APR September/October 2020 - 57
APR September/October 2020 - 58
APR September/October 2020 - 59
APR September/October 2020 - 60
APR September/October 2020 - 61
APR September/October 2020 - 62
APR September/October 2020 - 63
APR September/October 2020 - 64
APR September/October 2020 - 65
APR September/October 2020 - 66
APR September/October 2020 - 67
APR September/October 2020 - 68
APR September/October 2020 - 69
APR September/October 2020 - 70
APR September/October 2020 - 71
APR September/October 2020 - 72
APR September/October 2020 - 73
APR September/October 2020 - 74
APR September/October 2020 - 75
APR September/October 2020 - 76
APR September/October 2020 - 77
APR September/October 2020 - 78
APR September/October 2020 - 79
APR September/October 2020 - 80
APR September/October 2020 - 81
APR September/October 2020 - 82
APR September/October 2020 - 83
APR September/October 2020 - 84
APR September/October 2020 - 85
APR September/October 2020 - 86
APR September/October 2020 - 87
APR September/October 2020 - 88
APR September/October 2020 - 89
APR September/October 2020 - 90
APR September/October 2020 - 91
APR September/October 2020 - 92
APR September/October 2020 - 93
APR September/October 2020 - 94
APR September/October 2020 - 95
APR September/October 2020 - 96
APR September/October 2020 - 97
APR September/October 2020 - 98
APR September/October 2020 - 99
APR September/October 2020 - 100
APR September/October 2020 - 101
APR September/October 2020 - 102
APR September/October 2020 - 103
APR September/October 2020 - 104
APR September/October 2020 - 105
APR September/October 2020 - 106
APR September/October 2020 - 107
APR September/October 2020 - 108
APR September/October 2020 - 109
APR September/October 2020 - 110
APR September/October 2020 - 111
APR September/October 2020 - 112
APR September/October 2020 - 113
APR September/October 2020 - 114
APR September/October 2020 - 115
APR September/October 2020 - 116
APR September/October 2020 - 117
APR September/October 2020 - 118
APR September/October 2020 - 119
APR September/October 2020 - 120
APR September/October 2020 - 121
APR September/October 2020 - 122
APR September/October 2020 - 123
APR September/October 2020 - 124
APR September/October 2020 - 125
APR September/October 2020 - 126
APR September/October 2020 - 127
APR September/October 2020 - 128
APR September/October 2020 - 129
APR September/October 2020 - 130
APR September/October 2020 - 131
APR September/October 2020 - 132
APR September/October 2020 - 133
APR September/October 2020 - 134
APR September/October 2020 - 135
APR September/October 2020 - 136
APR September/October 2020 - 137
APR September/October 2020 - 138
APR September/October 2020 - 139
APR September/October 2020 - 140
APR September/October 2020 - 141
APR September/October 2020 - 142
APR September/October 2020 - 143
APR September/October 2020 - 144
APR September/October 2020 - 145
APR September/October 2020 - 146
APR September/October 2020 - 147
APR September/October 2020 - 148
APR September/October 2020 - 149
APR September/October 2020 - 150
APR September/October 2020 - 151
APR September/October 2020 - 152
APR September/October 2020 - 153
APR September/October 2020 - 154
APR September/October 2020 - 155
APR September/October 2020 - 156
APR September/October 2020 - 157
APR September/October 2020 - 158
APR September/October 2020 - 159
APR September/October 2020 - 160
APR September/October 2020 - 161
APR September/October 2020 - 162
APR September/October 2020 - 163
APR September/October 2020 - 164
APR September/October 2020 - 165
APR September/October 2020 - 166
APR September/October 2020 - 167
APR September/October 2020 - 168
APR September/October 2020 - Cover3
APR September/October 2020 - Cover4
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/apr-innovations-at-interphex-guide-april-2022
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/APRNovDec2020
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/APRSeptOct2020
https://www.nxtbookmedia.com